Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 11;31(Suppl 1):120-128.
doi: 10.31138/mjr.31.1.120. eCollection 2020 Jun.

Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium

Katerina Chatzidionysiou  1
Affiliations
Review

Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium

Katerina Chatzidionysiou. Mediterr J Rheumatol. .
No abstract available

Keywords: JAK inhibitors; biologics; methotrexate; rheumatoid arthritis; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. DMARDs, disease-modifying antirheumatic drugs; IFN, interferon; IL, interleukin; IL6R, interleukin 6 receptor; INFγ, interferon γ; JAK-STAT, Janus Kinase/Signal Transducer and Activator of Transcription proteins; mAb, monoclonalantibody; MHC, major histocompatibility complex; mIL6R, membraneinterleukin 6 receptor; sIL-6R, soluble interleukin 6 receptor; TCR, T cellreceptor; TNF, tumor necrosis factor.
Figure 2.
Figure 2.
ACR70 response and remission rates (based on DAS28<2.6) for tofacitinib, baricitinib and upadacitinib in DMARD naïve RA patients. All three JAK inhibitors yielded significantly higher clinical efficacy compared to methotrexate (MTX).
Figure 3.
Figure 3.
ACR70 response and remission rates (based on DAS28<2.6) for tofacitinib, baricitinib and upadacitinib in csDMARDs-IR (inadequate responders) RA patients. The JAK inhibitors were associated with significant clinical efficacy compared to methotrexate (MTX) and in some of these trials compared also to a bDMARD (ADA=adalimumab).
Figure 4.
Figure 4.
ACR70 response and remission rates (based on DAS28<2.6) for tofacitinib, baricitinib and upadacitinib in RA patients who have failed one or more bDMARDs.
See this image and copyright information in PMC

References

    1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001. - PubMed
    1. Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008;58(9):2642–51. - PubMed
    1. Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ, British Society for Rheumatology Biologics Register Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56(1):13–20. - PubMed
    1. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62(1):22–32. - PubMed
    1. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol 2015;44(6):431–7. - PubMed

LinkOut - more resources